Best Peptides for Weight Loss

As of October 2026, the best peptides for weight loss, meaning the ones with the strongest human evidence, are FDA-approved prescription medications built on natural gut-hormone peptides: tirzepatide (Zepbound®) and semaglutide (Wegovy®), plus the older daily option liraglutide (Saxenda®). In large randomized trials, adults on the highest tirzepatide dose lost an average of 20.9% of their body weight over 72 weeks, and adults on semaglutide lost an average of 14.9% over 68 weeks. The peptides promoted online for fat loss, such as BPC-157, AOD-9604, CJC-1295 and MOTS-c, are not FDA-approved for weight loss and have nothing like that level of human data behind them. Trial averages are not promises: individual results vary, and every one of these peptides for weight loss requires a prescription and a medical evaluation first.

Key Takeaways

• The peptide medications FDA-approved for weight management are tirzepatide, semaglutide (weekly injection and daily tablet) and liraglutide. Setmelanotide is approved only for specific rare genetic forms of obesity.
• In the only head-to-head trial, tirzepatide produced an average loss of 20.2% versus 13.7% for semaglutide at 72 weeks.
• Not every GLP-1 medication is a peptide: orforglipron (Foundayo), approved in April 2026, is a non-peptide pill.
• BPC-157, AOD-9604, CJC-1295, ipamorelin and MOTS-c are not FDA-approved. FDA lists specific safety concerns for them, and a July 2026 advisory committee vote on several peptides was non-binding.
• Stopping treatment usually means regaining weight: one year after stopping semaglutide, trial participants had regained about two-thirds of the weight they lost.
• Compounded and “research use only” versions are not FDA-reviewed. FDA had received 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026.

Weight Loss Peptides at a Glance: FDA Status and Evidence (as of October 2026)

This scorecard covers every peptide patients commonly ask us about. The first five rows are the GLP-1 peptides and related medications that are FDA-approved for some form of weight management and are available as prescription weight loss injections (or, for semaglutide, a tablet). The rest are investigational or unapproved, and are listed for information only.

Figures are trial averages, not promises. Individual results vary with dose, tolerance, medical history and lifestyle.

What Are Peptides for Weight Loss?

Peptides are short chains of amino acids, the same building blocks that make up proteins. Your body uses thousands of them as chemical messengers. Two matter most for weight: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), gut hormones released after you eat that help signal fullness and manage blood sugar.

The natural versions break down within minutes. The prescription weight loss peptides are lab-modified versions built to last far longer. Semaglutide, for example, has an elimination half-life of about one week, according to the FDA-approved Wegovy prescribing information on DailyMed, which is why it can be taken once a week. So when people ask what peptides for weight loss actually are, the honest answer is that the ones with real evidence are prescription medications, not supplements.

Is Ozempic a Peptide? Is Mounjaro?

Yes to both. The Wegovy label describes semaglutide (the active ingredient in Ozempic® and Wegovy) as “a GLP-1 analogue with 94% sequence homology to human GLP-1,” and notes its peptide backbone is produced by yeast fermentation. The Zepbound prescribing information states that tirzepatide (the active ingredient in Mounjaro® and Zepbound) is based on the GIP sequence.

The scope matters, though. Ozempic and Mounjaro are FDA-approved for type 2 diabetes. The weight-management versions of the same molecules are Wegovy and Zepbound, which have their own approved indications and dosing. Our comparison of Ozempic, Wegovy and Mounjaro breaks down those differences.

Peptide or Not? Sorting What’s Sold for Weight Loss

A lot of products get labeled “peptides” online. Some are, some aren’t, and some are peptides with no prescription effect at all:

How Weight Loss Peptides Work

The approved weight loss peptides mimic hormones your gut already makes. Per the Wegovy label, “GLP-1 is a physiological regulator of appetite and caloric intake,” and semaglutide delays gastric emptying, so food leaves your stomach more slowly and fullness lasts longer. GLP-1 peptides also boost insulin release when blood sugar rises. In practice, patients usually describe this as less “food noise” and feeling satisfied on smaller portions. Our article on why we’re always hungry explains the appetite signals involved.

Tirzepatide adds a second pathway by also activating the GIP receptor, which helps explain why it produced larger average losses in trials. Researchers are also testing other hormone pathways:

• Amylin (another fullness hormone, released with insulin): cagrilintide, an amylin analogue, is being studied in combination with semaglutide.
• Glucagon: retatrutide adds glucagon-receptor activity to GIP and GLP-1, aiming to increase energy use.
• MC4R (a brain receptor in the leptin pathway): setmelanotide works here, which is why it helps only people whose obesity comes from specific genetic defects in that pathway.

None of these peptides replaces diet and activity. The Wegovy and Zepbound labels both call for use “in combination with a reduced-calorie diet and increased physical activity.”

The FDA-Approved Peptides for Weight Loss, Ranked by Evidence

Tirzepatide (Zepbound®)

Tirzepatide has the largest average weight loss of any approved option. In the SURMOUNT-1 trial published in NEJM (2,539 adults with obesity or overweight, no diabetes), average loss at 72 weeks was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, versus 3.1% on placebo. Half of the people on 10 mg and 57% on 15 mg lost at least 20% of their body weight, compared with 3% on placebo.

FDA approved Zepbound in November 2023 for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure or type 2 diabetes. In December 2024 it also became the first medication approved for moderate-to-severe obstructive sleep apnea in adults with obesity (see tirzepatide and sleep apnea). Treatment starts low and increases gradually, with at least four weeks between dose steps. You can read more about tirzepatide, Mounjaro and Zepbound or see what tirzepatide weight loss results typically look like over time.

Semaglutide Injection (Wegovy®)

Semaglutide is the most studied peptide in the category. In the STEP 1 trial in NEJM (1,961 adults), weekly semaglutide 2.4 mg produced an average loss of 14.9% at 68 weeks versus 2.4% on placebo, about 15.3 kg (34 lb) versus 2.6 kg. Of those on semaglutide, 86.4% lost at least 5% of their weight, 69.1% lost at least 10%, and 50.5% lost at least 15%.

Semaglutide also has heart data no other weight-loss peptide can yet match. The SELECT trial followed 17,604 adults with existing cardiovascular disease and a BMI of 27 or higher but no diabetes. Major cardiovascular events (heart attack, stroke or cardiovascular death) occurred in 6.5% of the semaglutide group versus 8.0% on placebo, a 20% lower relative risk. Wegovy injection is approved for weight reduction and maintenance in adults and children 12 and older, for cardiovascular risk reduction in adults with established heart disease and obesity or overweight, and, under accelerated approval, for a form of fatty-liver disease called MASH. If you’re considering it, see our page on semaglutide treatment in Pembroke Pines and our breakdown of how much weight you can lose on semaglutide.

Semaglutide Tablet (Wegovy® Tablets)

Oral peptides used to be impractical because the stomach breaks them down. The once-daily Wegovy tablet gets around this. In the OASIS 4 trial in NEJM (307 adults), oral semaglutide led to an average loss of 13.6% at 64 weeks versus 2.2% on placebo. Digestive side effects were common: 74.0% versus 42.2% on placebo. Wegovy tablets are approved for adults. The pill is still a peptide (the same semaglutide molecule), which sets it apart from orforglipron below.

Liraglutide (Saxenda®)

Liraglutide is an older GLP-1 peptide, taken daily rather than weekly. In the SCALE trial in NEJM (3,731 adults), liraglutide 3.0 mg led to an average loss of 8.4 kg (about 18.5 lb) at 56 weeks versus 2.8 kg on placebo. 63.2% lost at least 5% of their weight, compared with 27.1% on placebo. Per the NIDDK’s guide to prescription weight-loss medications, it’s approved for adults and children 12 and older. It produces less weight loss than the weekly options but has the longest track record.

Setmelanotide (Imcivree®)

Setmelanotide is a specialized peptide approved only for certain rare genetic conditions (such as POMC or LEPR deficiency) confirmed by genetic testing, for people 6 and older. In phase 3 trials in The Lancet Diabetes & Endocrinology, 80% of patients with POMC deficiency (8 of 10) and 45% with LEPR deficiency (5 of 11) lost at least 10% of their weight at about one year. It isn’t a treatment for common obesity.

One GLP-1 Pill That Isn’t a Peptide: Orforglipron

FDA’s list of novel drug approvals for 2026 includes Foundayo (orforglipron), approved April 1, 2026, for weight reduction and maintenance. As Healio reported at approval, orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist. It’s worth knowing about because it shows that “GLP-1” and “peptide” aren’t the same thing.

All trial results above are group averages from controlled studies. Your own results will depend on your health, dose tolerance and the lifestyle changes you make alongside treatment.

Tirzepatide vs Semaglutide: What the Head-to-Head Trial Found

Most comparisons between these two peptides set separate trials side by side, which can mislead because the trials enrolled different people. SURMOUNT-5, published in NEJM in 2025, compared them directly in 751 adults with obesity and no diabetes. At 72 weeks, average weight loss was 20.2% with tirzepatide versus 13.7% with semaglutide, and waist circumference fell by 18.4 cm versus 13.0 cm.

Two caveats are worth knowing. The trial was open-label (participants knew which drug they were taking), and it was funded by Eli Lilly, which makes tirzepatide. The results are still the clearest direct evidence available.

That doesn’t make tirzepatide the right choice for everyone. Which peptide is “best” for one person depends on how they tolerate side effects, their medical history, other conditions (semaglutide has the SELECT heart data; tirzepatide has the sleep apnea approval), insurance coverage and supply. Our deeper comparison of semaglutide vs. tirzepatide covers these trade-offs, and we also explain what’s involved in switching from semaglutide to tirzepatide.

Peptides vs. GLP-1: Why the Question Is Misleading

Many people search “peptides vs. GLP-1” as if they were two different kinds of treatment. They mostly aren’t. Semaglutide, tirzepatide and liraglutide, the leading GLP-1 medications, are themselves peptides. When a clinic or website sets “peptides” against GLP-1s, it usually means unapproved compounds like AOD-9604 or CJC-1295 on one side and FDA-approved GLP-1 peptides on the other.

The comparison that actually matters is this: FDA-approved peptide medications tested in trials of thousands of people over more than a year, versus peptides without FDA approval for weight loss and without comparable trials. And because orforglipron is a GLP-1 pill that isn’t a peptide, “peptide” by itself tells you nothing about whether something works.

Investigational Peptides: Retatrutide and CagriSema

FDA status as of October 2026: neither retatrutide nor cagrilintide-semaglutide (CagriSema) is FDA-approved for any use. Both are still being studied.

Retatrutide activates three hormone receptors (GIP, GLP-1 and glucagon). In its phase 2 trial in NEJM (338 adults), the 12 mg dose produced an average loss of 24.2% at 48 weeks versus 2.1% on placebo. Digestive side effects rose with dose, and heart rate increased, peaking at 24 weeks. In May 2026, Eli Lilly announced topline phase 3 results from TRIUMPH-1, reported by TCTMD: in 2,339 adults over 80 weeks, average losses were 19.0%, 25.9% and 28.3% on the 4, 9 and 12 mg doses versus 2.2% on placebo. These are the manufacturer’s topline numbers from May 2026; the full trial was published in NEJM at the end of September 2026, and figures in that paper can differ depending on the statistical analysis used. Long-term safety data and cardiovascular outcomes are not yet available.

CagriSema combines the amylin analogue cagrilintide with semaglutide. In the REDEFINE 1 trial in NEJM (3,417 adults), it led to a 20.4% average loss at 68 weeks versus 3.0% on placebo, with digestive side effects in 79.6% versus 39.9%.

Products sold online as “retatrutide” are not the investigational drug used in these trials. FDA’s statement on its concerns with unapproved GLP-1 drugs used for weight loss says it has warned companies selling retatrutide, along with semaglutide, tirzepatide and other compounds, labeled “for research purposes” or “not for human consumption.” For a closer look at the trial data and FDA timeline, see our article on retatrutide side effects and its FDA timeline. If you’re interested in a medication that’s still in trials, talk with a licensed clinician about whether a clinical trial or an approved option fits your situation.

Peptides Marketed Online for Weight Loss: What the Evidence and FDA Say

This section reports regulatory status and safety information only. It is not a recommendation of any substance below. Facts are current as of October 2026.

Tesamorelin

Tesamorelin is FDA-approved, but not for weight loss. The Egrifta WR prescribing information limits it to reducing excess abdominal fat in adults with HIV who have lipodystrophy, and states it is “not indicated for weight loss management as it has a weight neutral effect.” The trial behind its approval, published in NEJM in 2007, enrolled 412 HIV patients and found visceral (deep belly) fat fell 15.2% over 26 weeks versus a 5.0% rise on placebo. Those results apply to that population only.

Sermorelin

Sermorelin is another growth-hormone-releasing hormone analogue often marketed for body composition. It isn’t on NIDDK’s list of FDA-approved weight-management medications, and no FDA label lists weight loss as a use.

AOD-9604, CJC-1295, Ipamorelin, MOTS-c, BPC-157 and TB-500

FDA keeps a public page on bulk drug substances for compounding that may present significant safety risks (content current as of April 22, 2026). BPC-157, AOD-9604, CJC-1295, MOTS-c and TB-500 now appear in its table of substances “nominated but withdrawn”: they were previously in Category 2 and their nominations were withdrawn. That change is not an approval, and the page still records FDA’s safety concerns:

• BPC-157: risk of immune reactions (immunogenicity) and limited safety information.
• AOD-9604: serious adverse events possibly associated with use, with causality unclear.
• CJC-1295: serious adverse events, including increased heart rate and systemic vasodilatory reactions, with limited clinical data.
• MOTS-c and TB-500: FDA identified no human exposure data.
• Ipamorelin: remains in Category 2, with serious adverse events including death reported when given intravenously.

The July 2026 FDA Advisory Committee Vote

On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee considered whether seven peptides could be added to the list of substances pharmacies may use in compounding. Each was reviewed for specific conditions, not weight loss in general: BPC-157 for ulcerative colitis, TB-500 for wound healing, KPV for wound healing and inflammatory conditions, and MOTS-c for obesity and osteoporosis, along with emideltide, Semax and Epitalon for other conditions. FDA’s meeting page notes that “advisory committees make non-binding recommendations to the FDA.”

ABC News reported that the committee narrowly recommended six of the seven (all but emideltide), while FDA staff scientists unanimously opposed adding them. FDA hadn’t posted the vote outcome on its meeting page as of its August 6, 2026 update, and as of October 2026 we found no final FDA action. Even if FDA eventually adds a substance to a compounding list, that is not the same as finding it safe or effective.

The bottom line: none of these compounds has the kind of large human weight-loss trials behind the approved peptides. If you’ve been offered one, review it with a licensed clinician before using it.

Are Peptides Safe for Weight Loss? Side Effects and Who Shouldn’t Use Them

The approved peptides have well-documented safety profiles, and that’s a big part of why they’re the safer choice. “Well-documented” doesn’t mean risk-free, though. Here’s what the labels and trials show about peptides for weight loss side effects.

Common Side Effects

The most common side effects are digestive: nausea, diarrhea, vomiting, constipation and abdominal pain. In STEP 1, these were mostly mild to moderate and faded over time, and 4.5% of participants stopped semaglutide because of digestive side effects versus 0.8% on placebo. In SURMOUNT-1, 4.3% to 7.1% stopped tirzepatide because of side effects, depending on dose, versus 2.6% on placebo. Gradual dose increases are designed to reduce these effects. We have practical guides on semaglutide side effects and how to manage nausea on semaglutide.

Serious Warnings on the Labels

• Thyroid C-cell tumors: both Wegovy and Zepbound carry a boxed warning based on rodent studies. They’re contraindicated if you or a family member has had medullary thyroid carcinoma (MTC) or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2).
• Pancreatitis (inflammation of the pancreas).
• Gallbladder disease, including gallstones.
• Acute kidney injury, usually from dehydration after vomiting or diarrhea.
• Serious allergic reactions.
• Low blood sugar when combined with insulin or sulfonylureas.
• Diabetic retinopathy complications in people with type 2 diabetes.
• Pulmonary aspiration during anesthesia or deep sedation: tell your surgeon and anesthesiologist you’re taking one before any procedure.
• Increased heart rate (listed for Wegovy).

Zepbound shouldn’t be combined with other tirzepatide products or any GLP-1 receptor agonist.

The Extra Risk of Compounded and “Research” Peptides

FDA’s statement on unapproved GLP-1 drugs is clear that compounded drugs are not FDA-approved or reviewed for safety, effectiveness or quality. As of May 31, 2026, FDA had received 990 adverse-event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide, and says these are likely underreported. It also describes dosing errors that led to hospitalizations and counterfeit Ozempic found in the U.S. supply chain, and notes that salt forms such as semaglutide sodium or acetate have no known lawful basis for compounding.

When to Seek Urgent Care

Call your prescriber right away, or get emergency care, if you notice any of these while taking a weight-loss peptide:

• Severe abdominal pain that won’t go away, with or without vomiting, sometimes spreading to your back (possible pancreatitis).
• Pain in your upper right abdomen, fever, yellowing of your skin or eyes, or clay-colored stools (possible gallbladder problems).
• Swelling of your face, lips, tongue or throat, trouble breathing or swallowing, a severe rash, fainting or a racing heartbeat (possible severe allergic reaction).
• Ongoing vomiting or diarrhea with very little urine, dizziness or extreme thirst (possible dehydration and kidney strain).
• A lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath (report to your clinician given the thyroid warning).
• Shakiness, sweating, confusion or dizziness if you also take diabetes medication (possible low blood sugar).

Call 911 for trouble breathing, swelling of the throat or any symptom that feels life-threatening.

What Happens When You Stop Taking Weight-Loss Peptides

This is the part most “best peptides” lists leave out. These medications treat obesity as a chronic condition, and stopping usually brings weight back. Two trials show how much:

NIDDK’s guidance agrees: people who stop these medications will probably regain some weight. That doesn’t mean treatment has to be lifelong for everyone, but stopping should be planned rather than abrupt.

Protecting Muscle and Keeping Your Results

When weight comes off quickly, some of it can be lean tissue. Our clinicians focus on three things to protect muscle and make results last: enough protein at each meal, resistance training a few times a week, and monitoring body composition, not just the number on the scale. Read more about tirzepatide and muscle loss, what to eat on semaglutide, and how to build exercise for weight loss into your routine. At Cardiomender, patients who are ready are coached toward maintenance habits and, where it’s medically appropriate, a supervised plan to taper medication over time. That plan is individual, and outcomes differ from person to person.

Before You Start Any Peptide: A 7-Question Safety Checklist

Whether a peptide comes from a clinic, a med spa or a website, ask these questions first. If the answer to any of them is “no” or “I don’t know,” stop and talk to a licensed clinician.

1. Is it FDA-approved for weight management? Check it against the approved list: tirzepatide (Zepbound), semaglutide (Wegovy), liraglutide (Saxenda), setmelanotide (Imcivree, genetic conditions only), plus non-peptide options such as orforglipron.
2. Is it the FDA-approved product, or a compounded or “research use only” version? FDA says compounded drugs aren’t reviewed for safety, effectiveness or quality, and “not for human consumption” products are exactly that.
3. Is it dispensed by a licensed pharmacy your clinician approves? NIDDK advises buying weight-loss medications from a pharmacy or online distributor approved by your health care professional.
4. Has someone reviewed your medical history? Including any personal or family history of medullary thyroid cancer or MEN 2, pancreatitis, gallbladder disease, kidney problems and pregnancy plans.
5. Will a clinician supervise your dose increases? The approved labels use gradual, monthly-or-slower dose steps to reduce side effects.
6. Are you combining it with another weight-loss product? NIDDK advises against combining weight-loss medications unless your clinician directs it, and the Zepbound label advises against using it with any GLP-1 receptor agonist.
7. What’s the plan for keeping your results? Given the regain data above, ask how nutrition, activity and any future taper will be handled.

Our weight loss FAQ answers many of the practical questions that come up next.

Who Is a Candidate for Peptide Weight-Loss Medication?

According to NIDDK, prescription weight-loss medications are generally for adults with a BMI of 30 or higher, or 27 or higher with a weight-related health problem such as high blood pressure or type 2 diabetes. Wegovy and Saxenda are also approved for adolescents 12 and older who meet pediatric criteria. A clinician still has to rule out reasons you shouldn’t take one, including the thyroid history above, a history of pancreatitis, pregnancy or plans for pregnancy, and interactions with your current medications.

NIDDK reports that adding medication to lifestyle changes leads to an average of 3% to 12% more weight loss of starting body weight after one year than lifestyle changes alone. Not every patient responds the same way, which is why progress is reviewed regularly.

Peptides aren’t the only option. NIDDK’s list also includes non-peptide medications such as phentermine-topiramate and orlistat, and some patients are better suited to those. Learn more about how phentermine works for weight loss.

How Long Do Weight-Loss Peptides Take to Work?

NIDDK notes that most weight loss on these medications happens in the first six months. Appetite changes often come earlier, but doses build up over several months, so the full effect takes time. For drug-specific timelines, see how long tirzepatide takes to work and how long semaglutide takes to work.

Peptides for Weight Loss in Women and Men

The approved peptides work the same way regardless of sex, and the major trials enrolled both women and men under the same eligibility criteria. A few label details matter specifically for women:

• Pregnancy planning: the Wegovy label advises stopping it at least two months before a planned pregnancy because of semaglutide’s long half-life. Our article on semaglutide and fertility covers this in more detail.
• Birth control pills: the Zepbound label advises women on oral contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Non-oral hormonal contraceptives aren’t expected to be affected.

For men, the evidence and the safety checklist above apply the same way. Peptides for weight loss in women and men should be chosen based on medical history, not marketing aimed at one sex.

Evidence First: How Cardiomender Weight Loss & Aesthetics Matches Patients to Approved Peptide Medications

Cardiomender Weight Loss & Aesthetics has offered medically supervised weight loss from its Pembroke Pines clinic since 2009, years before GLP-1 medications became household names. That experience shapes how we approach peptides:

• Evaluation before any prescription. Your medical history, labs and goals come first. Prescribing decisions are made by licensed clinicians on our team, including Yanara Diaz, FNP-BC.
• Evidence you can check. If you came from our peptide therapy page, the process starts the same way: a medical evaluation first, then a clear walk-through of which options are FDA-approved for your situation, what the trials showed and what the label risks are.
• In-person care, not just a prescription. Our medical weight loss program in Pembroke Pines includes nutrition guidance, lab work and ongoing monitoring of side effects and progress.
• A plan for after the medication. We coach patients toward habits that support maintenance and, when appropriate, toward a supervised taper, because the regain data shows that stopping without a plan rarely goes well.

We see patients from across South Florida, including Broward, Miami-Dade and Palm Beach counties, at our single location at 17009 Pines Blvd in Pembroke Pines.

Peptides for Weight Loss: Frequently Asked Questions

What is the best peptide for weight loss?

Among FDA-approved options, tirzepatide (Zepbound) produced the largest average weight loss in trials: 20.9% at the highest dose in SURMOUNT-1, and 20.2% versus 13.7% for semaglutide in the head-to-head SURMOUNT-5 trial. Still, the best choice for you depends on your health history, how you tolerate side effects, other conditions and coverage. That’s decided in a medical evaluation, not by a ranking.

Do peptides really work for weight loss?

The FDA-approved ones do, based on randomized trials involving thousands of people. Semaglutide and tirzepatide led to average losses of roughly 14% to 21% over about 16 months. The peptides marketed online for fat loss, such as AOD-9604, CJC-1295 or MOTS-c, don’t have comparable human trials, and FDA lists safety concerns for several of them.

Is Mounjaro a peptide?

Yes. Tirzepatide, the active ingredient in Mounjaro and Zepbound, is a modified peptide based on the GIP hormone sequence. Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is the version approved for chronic weight management and obstructive sleep apnea in adults with obesity.

What is the safest peptide for weight loss?

No peptide is risk-free. The safest choice is an FDA-approved product whose risks are known and printed on its label, dispensed by a licensed pharmacy and prescribed after a clinician screens your history. Unapproved, compounded or “research use” peptides add unknowns about contents, purity and dose.

What peptide gets rid of lower belly fat?

No peptide targets fat in one spot. Tesamorelin reduces deep abdominal fat, but it’s approved only for adults with HIV-related lipodystrophy, and its label says it isn’t indicated for weight loss. Overall weight loss with approved peptides does shrink the waistline: in SURMOUNT-5, waist size fell by an average of 18.4 cm with tirzepatide and 13.0 cm with semaglutide.

What are the downsides of taking peptides?

The main downsides are digestive side effects, rarer but serious risks such as pancreatitis and gallbladder disease, cost, and weight regain if you stop without a plan. Unapproved peptides add regulatory and quality risks on top of that, since FDA hasn’t reviewed them for safety or effectiveness.

Are peptides for weight loss FDA-approved?

Some are. As of October 2026, the peptides FDA-approved for weight management are tirzepatide (Zepbound), semaglutide (Wegovy injection and tablets) and liraglutide (Saxenda), plus setmelanotide (Imcivree) for specific rare genetic conditions. BPC-157, AOD-9604, CJC-1295, ipamorelin, MOTS-c, TB-500, sermorelin and retatrutide are not FDA-approved for weight loss.

Are there oral peptides for weight loss?

Yes. Wegovy tablets contain semaglutide, the same peptide as the injection, and led to an average 13.6% loss at 64 weeks in the OASIS 4 trial. Foundayo (orforglipron) is also an approved weight-loss pill, but it’s a non-peptide small molecule.

Can I combine peptides for weight loss?

Not without your clinician’s direction. The Zepbound label advises against using it with other tirzepatide products or any GLP-1 receptor agonist, and NIDDK advises against combining weight-loss medications unless a health care professional recommends it. Combining products you get online adds unknown risks.

Is BPC-157 a weight-loss peptide?

No. BPC-157 isn’t FDA-approved for any use, and when FDA’s advisory committee reviewed it in July 2026, it was for ulcerative colitis, not obesity. FDA’s compounding safety page cites a risk of immune reactions and limited safety information.

Does insurance cover weight-loss peptides?

Coverage varies widely by plan, by drug and by the condition being treated. Some plans cover these medications only for specific diagnoses, such as type 2 diabetes, heart disease or sleep apnea. Call our team and we can walk you through your options.

If you’re weighing peptides for weight loss, the first step is a medical evaluation to see which FDA-approved option, if any, fits your health and goals. Cardiomender Weight Loss & Aesthetics serves patients across South Florida from our Pembroke Pines clinic. Book your consultation at Cardiomender or call us at (954) 799-6439 to talk with our team about your options.